Key facts
- Notable investors include Chengdu Longchu Equity Investment Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Jianlin Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Jianlin Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jianlin Pharmaceutical
Manufacturer of pharmaceutical formulations intended to develop critical medicines for respiratory, cerebrovascular, anesthesia, and emergency care. The company offers inhalation solutions, nasal spray systems, dry powder inhalers, and injectable formulations, thereby enabling them to improve treatment precision, enhance patient safety, and accelerate therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2022
- Website
- jianlinpharma.com/
- Ownership
- Privately Held (backing)
Jianlin Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jianlin Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jianlin Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.